Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19
- PMID: 32980157
- PMCID: PMC7498226
- DOI: 10.1016/j.jaci.2020.09.002
Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19
Comment in
-
Reply.J Allergy Clin Immunol. 2020 Dec;146(6):1453-1454. doi: 10.1016/j.jaci.2020.07.037. Epub 2020 Sep 18. J Allergy Clin Immunol. 2020. PMID: 32980158 Free PMC article. No abstract available.
Comment on
-
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3. doi: 10.1016/j.jaci.2020.05.019. Epub 2020 May 26. J Allergy Clin Immunol. 2020. PMID: 32470486 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
